Radiation Oncology Journal

The Korean Society for Radiation Oncology (대한방사선종양학회)
권호 표지
DOI QR코드

DOI QR Code

Gene signature for prediction of radiosensitivity in human papillomavirus-negative head and neck squamous cell carcinoma

  • Kim, Su Il (Department of Biomedical Science and Technology, Graduate School, Kyung Hee University) ;
  • Kang, Jeong Wook (Department of Otolaryngology-Head and Neck Surgery, Kyung Hee University Medical Center) ;
  • Noh, Joo Kyung (Department of Biomedical Science and Technology, Graduate School, Kyung Hee University) ;
  • Jung, Hae Rim (Department of Otolaryngology-Head and Neck Surgery, Kyung Hee University Medical Center) ;
  • Lee, Young Chan (Department of Otolaryngology-Head and Neck Surgery, Kyung Hee University Medical Center) ;
  • Lee, Jung Woo (Department of Oral and Maxillofacial Surgery, School of Dentistry, Kyung Hee University) ;
  • Kong, Moonkyoo (Division of Lung & Head and Neck Oncology, Department of Radiation Oncology, Kyung Hee University Medical Center) ;
  • Eun, Young-Gyu (Department of Biomedical Science and Technology, Graduate School, Kyung Hee University)
  • Received : 2020.03.19
  • Accepted : 2020.05.06
  • Published : 2020.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: The probability of recurrence of cancer after adjuvant or definitive radiotherapy in patients with human papillomavirus-negative (HPV(-)) head and neck squamous cell carcinoma (HNSCC) varies for each patient. This study aimed to identify and validate radiation sensitivity signature (RSS) of patients with HPV(-) HNSCC to predict the recurrence of cancer after radiotherapy. Materials and Methods: Clonogenic survival assays were performed to assess radiosensitivity in 14 HNSCC cell lines. We identified genes closely correlated with radiosensitivity and validated them in The Cancer Genome Atlas (TCGA) cohort. The validated RSS were analyzed by ingenuity pathway analysis (IPA) to identify canonical pathways, upstream regulators, diseases and functions, and gene networks related to radiosensitive genes in HPV(-) HNSCC. Results: The survival fraction of 14 HNSCC cell lines after exposure to 2 Gy of radiation ranged from 48% to 72%. Six genes were positively correlated and 35 genes were negatively correlated with radioresistance, respectively. RSS was validated in the HPV(-) TCGA HNSCC cohort (n = 203), and recurrence-free survival (RFS) rate was found to be significantly lower in the radioresistant group than in the radiosensitive group (p = 0.035). Cell death and survival, cell-to-cell signaling, and cellular movement were significantly enriched in RSS, and RSSs were highly correlated with each other. Conclusion: We derived a HPV(-) HNSCC-specific RSS and validated it in an independent cohort. The outcome of adjuvant or definitive radiotherapy in HPV(-) patients with HNSCC can be predicted by analyzing their RSS, which might help in establishing a personalized therapeutic plan.

Keywords

References

  1. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006;24:2137-50. https://doi.org/10.1200/JCO.2005.05.2308
  2. Argiris A, Karamouzis MV, Raben D, Ferris RL. Head and neck cancer. Lancet 2008;371:1695-709. https://doi.org/10.1016/S0140-6736(08)60728-X
  3. Leemans CR, Braakhuis BJ, Brakenhoff RH. The molecular biology of head and neck cancer. Nat Rev Cancer 2011;11:9-22. https://doi.org/10.1038/nrc2982
  4. Smith RB, Sniezek JC, Weed DT, Wax MK; Microvascular Surgery Subcommittee of American Academy of Otolaryngology-Head and Neck Surgery. Utilization of free tissue transfer in head and neck surgery. Otolaryngol Head Neck Surg 2007;137:182-91. https://doi.org/10.1016/j.otohns.2007.04.011
  5. Vergeer MR, Doornaert PA, Rietveld DH, Leemans CR, Slotman BJ, Langendijk JA. Intensity-modulated radiotherapy reduces radiation-induced morbidity and improves health-related quality of life: results of a nonrandomized prospective study using a standardized follow-up program. Int J Radiat Oncol Biol Phys 2009;74:1-8. https://doi.org/10.1016/j.ijrobp.2008.07.059
  6. Gupta S, Kong W, Peng Y, Miao Q, Mackillop WJ. Temporal trends in the incidence and survival of cancers of the upper aerodigestive tract in Ontario and the United States. Int J Cancer 2009;125:2159-65. https://doi.org/10.1002/ijc.24533
  7. Gujral DM, Nutting CM. Patterns of failure, treatment outcomes and late toxicities of head and neck cancer in the current era of IMRT. Oral Oncol 2018;86:225-33. https://doi.org/10.1016/j.oraloncology.2018.09.011
  8. Schmidt S, Linge A, Zwanenburg A, et al. Development and validation of a gene signature for patients with head and neck carcinomas treated by postoperative radio(chemo)therapy. Clin Cancer Res 2018;24:1364-74. https://doi.org/10.1158/1078-0432.CCR-17-2345
  9. Ragin CC, Taioli E. Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: review and meta-analysis. Int J Cancer 2007;121:1813-20. https://doi.org/10.1002/ijc.22851
  10. Lohaus F, Linge A, Tinhofer I, et al. HPV16 DNA status is a strong prognosticator of loco-regional control after postoperative radiochemotherapy of locally advanced oropharyngeal carcinoma: results from a multicentre explorative study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). Radiother Oncol 2014;113:317-23. https://doi.org/10.1016/j.radonc.2014.11.011
  11. Gupta AK, Lee JH, Wilke WW, et al. Radiation response in two HPV-infected head-and-neck cancer cell lines in comparison to a non-HPV-infected cell line and relationship to signaling through AKT. Int J Radiat Oncol Biol Phys 2009;74:928-33. https://doi.org/10.1016/j.ijrobp.2009.03.004
  12. van den Broek GB, Wildeman M, Rasch CR, et al. Molecular markers predict outcome in squamous cell carcinoma of the head and neck after concomitant cisplatin-based chemoradiation. Int J Cancer 2009;124:2643-50. https://doi.org/10.1002/ijc.24254
  13. Linge A, Lock S, Gudziol V, et al. Low cancer stem cell marker expression and low hypoxia identify good prognosis subgroups in HPV(-) HNSCC after postoperative radiochemotherapy: a multicenter study of the DKTK-ROG. Clin Cancer Res 2016;22:2639-49. https://doi.org/10.1158/1078-0432.CCR-15-1990
  14. Foy JP, Bazire L, Ortiz-Cuaran S, et al. A 13-gene expression-based radioresistance score highlights the heterogeneity in the response to radiation therapy across HPV-negative HNSCC molecular subtypes. BMC Med 2017;15:165. https://doi.org/10.1186/s12916-017-0929-y
  15. de Jong MC, Ten Hoeve JJ, Grenman R, et al. Pretreatment microRNA expression impacting on epithelial-to-mesenchymal transition predicts intrinsic radiosensitivity in head and neck cancer cell lines and patients. Clin Cancer Res 2015;21:5630-8. https://doi.org/10.1158/1078-0432.CCR-15-0454
  16. Goldman M, Craft B, Swatloski T, et al. The UCSC Cancer Genomics Browser: update 2015. Nucleic Acids Res 2015;43(Database issue):D812-7. https://doi.org/10.1093/nar/gku1073
  17. Radmacher MD, McShane LM, Simon R. A paradigm for class prediction using gene expression profiles. J Comput Biol 2002;9:505-11. https://doi.org/10.1089/106652702760138592
  18. Ramaswamy S, Tamayo P, Rifkin R, et al. Multiclass cancer diagnosis using tumor gene expression signatures. Proc Natl Acad Sci U S A 2001;98:15149-54. https://doi.org/10.1073/pnas.211566398
  19. Simon R, Lam A, Li MC, Ngan M, Menenzes S, Zhao Y. Analysis of gene expression data using BRB-ArrayTools. Cancer Inform 2007;3:11-7.
  20. Ding D, Stokes W, Eguchi M, et al. Association between lymph node ratio and recurrence and survival outcomes in patients with oral cavity cancer. JAMA Otolaryngol Head Neck Surg 2019;145:53-61. https://doi.org/10.1001/jamaoto.2018.2974
  21. Yu J, Gu X, Yi S. Ingenuity pathway analysis of gene expression profiles in distal nerve stump following nerve injury: insights into Wallerian degeneration. Front Cell Neurosci 2016;10:274.
  22. Barretina J, Caponigro G, Stransky N, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012;483:603-7. https://doi.org/10.1038/nature11003
  23. Kim DU, Kwak B, Kim SW. Phosphodiesterase 4B is an effective therapeutic target in colorectal cancer. Biochem Biophys Res Commun 2019;508:825-31. https://doi.org/10.1016/j.bbrc.2018.12.004
  24. Deng M, Gui X, Kim J, et al. LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration. Nature 2018;562:605-9. https://doi.org/10.1038/s41586-018-0615-z
  25. Anderson AM, Kalimutho M, Harten S, Nanayakkara DM, Khanna KK, Ragan MA. The metastasis suppressor RARRES3 as an endogenous inhibitor of the immunoproteasome expression in breast cancer cells. Sci Rep 2017;7:39873. https://doi.org/10.1038/srep39873
  26. Tang W, Wallace TA, Yi M, et al. IFNL4-ΔG allele is associated with an interferon signature in tumors and survival of African-American men with prostate cancer. Clin Cancer Res 2018;24:5471-81. https://doi.org/10.1158/1078-0432.CCR-18-1060
  27. Sigurdson AJ, Brenner AV, Roach JA, et al. Selected single-nucleotide polymorphisms in FOXE1, SERPINA5, FTO, EVPL, TICAM1 and SCARB1 are associated with papillary and follicular thyroid cancer risk: replication study in a German population. Carcinogenesis 2016;37:677-84. https://doi.org/10.1093/carcin/bgw047
  28. Appukuttan A, Flacke JP, Flacke H, Posadowsky A, Reusch HP, Ladilov Y. Inhibition of soluble adenylyl cyclase increases the radiosensitivity of prostate cancer cells. Biochim Biophys Acta 2014;1842(12 Pt B):2656-63. https://doi.org/10.1016/j.bbadis.2014.09.008
  29. Shime H, Matsumoto M, Seya T. Double-stranded RNA promotes CTL-independent tumor cytolysis mediated by CD11b+Ly6G+ intratumor myeloid cells through the TICAM-1 signaling pathway. Cell Death Differ 2017;24:385-96. https://doi.org/10.1038/cdd.2016.131
  30. Liang YW, Zheng J, Li X, Zheng W, Chen T. Selenadiazole derivatives as potent thioredoxin reductase inhibitors that enhance the radiosensitivity of cancer cells. Eur J Med Chem 2014;84:335-42. https://doi.org/10.1016/j.ejmech.2014.07.032
  31. Selenius M, Hedman M, Brodin D, et al. Effects of redox modulation by inhibition of thioredoxin reductase on radiosensitivity and gene expression. J Cell Mol Med 2012;16:1593-605. https://doi.org/10.1111/j.1582-4934.2011.01469.x
  32. Smart DK, Ortiz KL, Mattson D, et al. Thioredoxin reductase as a potential molecular target for anticancer agents that induce oxidative stress. Cancer Res 2004;64:6716-24. https://doi.org/10.1158/0008-5472.CAN-03-3990
  33. Luo M, Cai W, Li K, Liu J, Xue W, Liu Y. Effect of PDLIM4 gene on the prognosis of glioma and its cell radiosensitivity. Zhonghua Fang She Yi Xue Yu Fang Hu Za Zhi (Chin J Radiol Med Prot) 2017;37:725-9, 762.
  34. Yoo JY, Jung NC, Lee JH, et al. Pdlim4 is essential for CCR7-JNK-mediated dendritic cell migration and F-actin-related dendrite formation. FASEB J 2019;33:11035-44. https://doi.org/10.1096/fj.201901031
  35. Ning S, Budas GR, Churchill EN, Chen CH, Knox SJ, Mochly-Rosen D. Mitigation of radiation-induced dermatitis by activation of aldehyde dehydrogenase 2 using topical alda-1 in mice. Radiat Res 2012;178:69-74. https://doi.org/10.1667/RR2861.1
  36. Jiang Z, Xu Y, Cai S. CXCL10 expression and prognostic significance in stage II and III colorectal cancer. Mol Biol Rep 2010;37:3029-36. https://doi.org/10.1007/s11033-009-9873-z
  37. Li C, Wang Z, Liu F, et al. CXCL10 mRNA expression predicts response to neoadjuvant chemoradiotherapy in rectal cancer patients. Tumour Biol 2014;35:9683-91. https://doi.org/10.1007/s13277-014-2234-0
  38. Lukas RV, Hasan Y, Nicholas MK, Salgia R. ROS1 rearranged non-small cell lung cancer brain metastases respond to low dose radiotherapy. J Clin Neurosci 2015;22:1978-9. https://doi.org/10.1016/j.jocn.2015.04.009

Cited by

  1. Survey of radiation field and dose in human papillomavirus-positive oropharyngeal cancer: is de-escalation actually applied in clinical practice? vol.39, pp.3, 2020, https://doi.org/10.3857/roj.2021.00556